Literature DB >> 22481272

Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase.

Ciriana Orabona1, Maria Teresa Pallotta, Ursula Grohmann.   

Abstract

Indoleamine 2,3-dioxygenase (IDO), a metabolic enzyme that catalyzes tryptophan conversion into kynurenines, is a crucial regulator of immunity. Altered IDO activity is often associated with pathology, including neoplasia and autoimmunity. IDO is highly expressed in dendritic cells (DCs) that exploit the enzyme's activity and the production of tryptophan catabolites to regulate immune responses by acting on several cell types, including T lymphocytes, of which they promote a regulatory phenotype. IDO also contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that, once bound by distinct molecular partners, will either promote degradation or initiate signaling activity and self-maintenance of the enzyme. We here discuss how ITIM-dependent molecular events can affect the functional plasticity of IDO by modifying the protein half-life and its enzymic and nonenzymic functions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22481272      PMCID: PMC3409287          DOI: 10.2119/molmed.2012.00029

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  91 in total

1.  Suppression of autoimmune disease and of massive lymphadenopathy in MRL/Mp-lpr/lpr mice lacking tyrosine kinase Fyn (p59fyn).

Authors:  T Takahashi; T Yagi; S Kakinuma; A Kurokawa; T Okada; K Takatsu; S Aizawa; T Katagiri
Journal:  J Immunol       Date:  1997-09-01       Impact factor: 5.422

Review 2.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

3.  Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells.

Authors:  Yumiko Matsumura; Takashi Kobayashi; Kenji Ichiyama; Ryoko Yoshida; Masayuki Hashimoto; Tomohito Takimoto; Kentaro Tanaka; Takatoshi Chinen; Takashi Shichita; Tony Wyss-Coray; Katsuaki Sato; Akihiko Yoshimura
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

Review 4.  Turning NF-kappaB and IRFs on and off in DC.

Authors:  Tsuneyasu Kaisho; Takashi Tanaka
Journal:  Trends Immunol       Date:  2008-06-03       Impact factor: 16.687

5.  SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses.

Authors:  Selinda J Orr; Nuala M Morgan; Richard J Buick; Caroline R Boyd; Joanne Elliott; James F Burrows; Caroline A Jefferies; Paul R Crocker; James A Johnston
Journal:  J Biol Chem       Date:  2006-11-30       Impact factor: 5.157

6.  Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.

Authors:  Kota Iwahori; Satoshi Serada; Minoru Fujimoto; Shintaro Nomura; Tadashi Osaki; Chun Man Lee; Hiroyuki Mizuguchi; Tsuyoshi Takahashi; Barry Ripley; Meinoshin Okumura; Ichiro Kawase; Tadamitsu Kishimoto; Tetsuji Naka
Journal:  Int J Cancer       Date:  2010-12-02       Impact factor: 7.396

Review 7.  Cytokine signaling modules in inflammatory responses.

Authors:  John J O'Shea; Peter J Murray
Journal:  Immunity       Date:  2008-04       Impact factor: 31.745

8.  Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase.

Authors:  Hiroshi Sugimoto; Shun-ichiro Oda; Takashi Otsuki; Tomoya Hino; Tadashi Yoshida; Yoshitsugu Shiro
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

9.  Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease.

Authors:  Luigina Romani; Francesca Fallarino; Antonella De Luca; Claudia Montagnoli; Carmen D'Angelo; Teresa Zelante; Carmine Vacca; Francesco Bistoni; Maria C Fioretti; Ursula Grohmann; Brahm H Segal; Paolo Puccetti
Journal:  Nature       Date:  2008-01-10       Impact factor: 49.962

10.  A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice.

Authors:  Ursula Grohmann; Francesca Fallarino; Roberta Bianchi; Ciriana Orabona; Carmine Vacca; Maria C Fioretti; Paolo Puccetti
Journal:  J Exp Med       Date:  2003-06-30       Impact factor: 14.307

View more
  32 in total

1.  The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells.

Authors:  Sara Trabanelli; Darina Očadlíková; Marilena Ciciarello; Valentina Salvestrini; Mariangela Lecciso; Camilla Jandus; Richard Metz; Cecilia Evangelisti; Lisa Laury-Kleintop; Pedro Romero; George C Prendergast; Antonio Curti; Roberto M Lemoli
Journal:  J Immunol       Date:  2014-01-03       Impact factor: 5.422

Review 2.  Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keynurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia.

Authors:  Marco Chilosi; Claudio Doglioni; Claudia Ravaglia; Guido Martignoni; Gian Luca Salvagno; Giovanni Pizzolo; Vincenzo Bronte; Venerino Poletti
Journal:  Biomedicines       Date:  2022-06-06

3.  The immunotherapeutic role of regulatory T cells in Leishmania (Viannia) panamensis infection.

Authors:  Allison Ehrlich; Tiago Moreno Castilho; Karen Goldsmith-Pestana; Wook-Jin Chae; Alfred L M Bothwell; Tim Sparwasser; Diane McMahon-Pratt
Journal:  J Immunol       Date:  2014-08-06       Impact factor: 5.422

4.  Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder.

Authors:  Jonathan Savitz; Wayne C Drevets; Chelsey M Smith; Teresa A Victor; Brent E Wurfel; Patrick S F Bellgowan; Jerzy Bodurka; T Kent Teague; Robert Dantzer
Journal:  Neuropsychopharmacology       Date:  2014-07-30       Impact factor: 7.853

5.  Deficiency of immunoregulatory indoleamine 2,3-dioxygenase 1in juvenile diabetes.

Authors:  Ciriana Orabona; Giada Mondanelli; Maria T Pallotta; Agostinho Carvalho; Elisa Albini; Francesca Fallarino; Carmine Vacca; Claudia Volpi; Maria L Belladonna; Maria G Berioli; Giulia Ceccarini; Susanna Mr Esposito; Raffaella Scattoni; Alberto Verrotti; Alessandra Ferretti; Giovanni De Giorgi; Sonia Toni; Marco Cappa; Maria C Matteoli; Roberta Bianchi; Davide Matino; Alberta Iacono; Matteo Puccetti; Cristina Cunha; Silvio Bicciato; Cinzia Antognelli; Vincenzo N Talesa; Lucienne Chatenoud; Dietmar Fuchs; Luc Pilotte; Benoît Van den Eynde; Manuel C Lemos; Luigina Romani; Paolo Puccetti; Ursula Grohmann
Journal:  JCI Insight       Date:  2018-03-22

6.  The Coevolution of IDO1 and AhR in the Emergence of Regulatory T-Cells in Mammals.

Authors:  Ursula Grohmann; Paolo Puccetti
Journal:  Front Immunol       Date:  2015-02-12       Impact factor: 7.561

Review 7.  Allergen recognition by innate immune cells: critical role of dendritic and epithelial cells.

Authors:  Fabián Salazar; Amir M Ghaemmaghami
Journal:  Front Immunol       Date:  2013-11-04       Impact factor: 7.561

Review 8.  AhR-Mediated, Non-Genomic Modulation of IDO1 Function.

Authors:  Maria Teresa Pallotta; Francesca Fallarino; Davide Matino; Antonio Macchiarulo; Ciriana Orabona
Journal:  Front Immunol       Date:  2014-10-15       Impact factor: 7.561

9.  Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes.

Authors:  Maria Teresa Pallotta; Ciriana Orabona; Roberta Bianchi; Carmine Vacca; Francesca Fallarino; Maria Laura Belladonna; Claudia Volpi; Giada Mondanelli; Marco Gargaro; Massimo Allegrucci; Vincenzo Nicola Talesa; Paolo Puccetti; Ursula Grohmann
Journal:  J Cell Mol Med       Date:  2014-09-12       Impact factor: 5.310

10.  The [1,2,4]Triazolo[4,3-a]pyridine as a New Player in the Field of IDO1 Catalytic Holo-Inhibitors.

Authors:  Silvia Fallarini; Irene P Bhela; Silvio Aprile; Enza Torre; Alice Ranza; Elena Orecchini; Eleonora Panfili; Maria T Pallotta; Alberto Massarotti; Marta Serafini; Tracey Pirali
Journal:  ChemMedChem       Date:  2021-08-27       Impact factor: 3.540

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.